The high affinity IL-2 receptor consists of three individual polypeptides, the α, β, and γ chains. Although the β and γ chains are shared by other lymphokine receptors, the α chain (CD25) is restricted to the IL-2 receptor, and is expressed by a variety of lymphoid cells (for review see reference [@B1]). The induction of CD25 in T cells is controlled at the transcriptional level through two DNA sequence elements, a proximal promoter/enhancer spanning the nucleotides between positions −54 and −584 in the mouse and −64 and −276 in humans, and a distal enhancer spanning ∼80 nucleotides around position −1350 in the mouse and −3750 (or −4150, according to another nomenclature) in the human CD25 gene ([@B2]--[@B6]). The activity of the promoter is rapidly induced by TCR-mediated signals or IL-1, and is controlled by an array of transcription factors, in particular by nuclear factor (NF)-κB, Elf-1, SRF, and HMG I(Y). The induction of the distal enhancer is controlled by IL-2, which induces signal transducer and activator of transcription (Stat)5, a member of the family of Stat transcription factors. Stat5 binds in concert with Elf-1, HMG I(Y), and GATA factors to multiple sites of the distal enhancer and contributes to its IL-2--mediated full expression in activated peripheral T lymphocytes ([@B4]--[@B6]).

Nuclear factor of activated T cell (NF-AT) factors comprise a family of transcription factors that contribute to the induced expression of numerous lymphokine and receptor genes in T cells. Similar to NF-κB factors, the nuclear translocation and activity of NF-AT factors is stimulated by TCR-mediated signals (for review see reference [@B7]). The DNA-binding domains of NF-AT and NF-κB/Rel factors share a common architecture ([@B8]) and, therefore, recognize overlapping DNA sequence motifs. These common properties between NF-AT and NF-κB (a major regulator of the CD25 promoter), and reports on the inhibition of CD25 expression by cyclosporin A ([@B9]) (an inhibitor of phosphatase calcineurin and, therefore, of nuclear translocation of NF-AT; reference [@B7]), prompted us to investigate whether NF-AT factors participate in CD25 promoter control. We show here that NF-ATp and NF-ATc bind to two sites located immediately upstream of the proximal CD25 promoter. Mutations within the NF-AT sites that suppress NF-AT binding impair CD25 promoter induction. Accordingly, the induction of CD25 is markedly delayed in T cells from NF-ATp--deficient mice. These findings implicate an important role for NF-AT factors in the inducible expression of high affinity IL-2 receptors after T cell activation.

Materials and Methods {#MaterialsMethods}
=====================

Cell Culture, Construction, and Transfection of CD25 Promoter Luciferase Plasmids.
----------------------------------------------------------------------------------

Murine El4 T thymoma cells and human Jurkat T leukemia cells were grown in RPMI medium containing 5% FCS. 2 × 10^7^ cells were transfected using the DEAE dextran protocol with 2.5 μg DNA of the CD25 promoter-luciferase reporter constructs alone or 0.5--2.5 μg DNA of reporter constructs (as indicated in the figure legends) along with 2 μg of a pLGP3-based vector expressing full-length murine NF-ATp (NF-AT1-C; reference [@B10]) or an RSV-LTR vector expressing human NF-ATc. Human 293 embryonic kidney cells were cultured in DMEM and transfected using a calcium phosphate transfection protocol. The luciferase reporter gene construct contains the wild-type murine CD25 promoter spanning the nucleotides up to position −2556 ([@B4]). Mutations in one or both of the NF-ATp binding sites around positions −585 and −650 were introduced into the promoter fragment from +1 to −800 using the QuikChange^TM^ site-directed mutagenesis kit (Stratagene Corp., La Jolla, CA) according to the manufacturer\'s instructions.

The following oligonucleotides were used for the mutagenesis of NF-AT sites:

\(i\) (−667) GCTAGACTTAAAATCT[AT]{.ul}CATTGCAGCTGTAAACAC (−632)

CGATCTGAATTTTAGA[TA]{.ul}GTAACGTCGACATTTGTG; and

\(ii\) (−596) CCCACACCCATG[AT]{.ul}ACTATGAATCGTGCATCAGAG (−562)

GGGTGAGGGTAC[TA]{.ul}TGATACTTAGCACGTAGTCTC

The underlined nucleotides indicate the mutations.

Immunofluorescence and Flow Cytometry.
--------------------------------------

For Ab stainings, 2--8 × 10^5^ cells were incubated on ice with mAbs at saturating concentrations. Fluorescein- and PE-labeled mAbs (Pharmingen, San Diego, CA) were used for two- and three-color immunofluorescence. For three-color flow cytometry, cells were stained first with biotinylated mAbs (PharMingen) for 15 min and were subsequently incubated with streptavidin-Red^670^ (GIBCO BRL, Eggenstein, Germany) and FITC- and PE-labeled mAbs for 15 min. Results obtained after analysis on a FACScan^®^ flow cytometer (Becton Dickinson, Mountain View, CA) using Lysys II software (Becton Dickinson) are shown as log dot-plots or histograms.

DNase I Footprint Protection Assays and EMSAs.
----------------------------------------------

In DNase I footprint protection assays, end-labeled DNA probes were prepared using \[γ-^32^P\]ATP and polynucleotide kinase. 10^4^ cpm (∼0.2 ng) of the following DNA fragments from the murine CD25 promoter ([@B4]) were used: (*a*) the HindIII--SacII fragment spanning the nucleotides from position +94 to −268; and (*b*) the SacII--BglII fragment spanning the nucleotides from −268 to −801. Fragment (*a*) was recut with EspI, and fragment (*b*) with DraI generating DNA fragments of ∼150--300 bp. These were incubated for 60 min with a bacterially expressed glutathione *S*-transferase (GST)--NF-ATp protein ([@B11]) containing the DNA-binding domain of murine NF-ATp. The samples were processed and fractionated on 6% polyacrylamide, 42% urea-sequencing gels.

Electromobility shift assays (EMSAs) were performed as previously described ([@B11]), using 2 μg nuclear proteins and 0.5 μg poly \[d(I-C)\]. In supershift EMSAs, 0.5 μg of either an NF-ATp--specific Ab (Cat. no. 06-348; UBI) or an NF-ATc--specific mAb (7A6) ([@B12]) were added to the incubations. When the DNA binding of GST--NF-ATp was tested, 0.5--1.5 μg of bacterial proteins prepared by affinity column chromatography ([@B11]) were incubated along with 0.5 μg poly \[d(I-C)\]. The following oligonucleotides were used as probes:

\(iii\) (−596)gatcCCCACACCCATGGAACTATGAATCGTG (−571)

GGGTGTGGGTACCTTGATACTTAGCACctag;

\(iv\) (−663)gatcGACTTAAAATCTTCCATTGCAGCTGTA (−635)

CTGAATTTTAGAAGGTAACGTCGACATctag; and

\(v\) (−667)GCTAGACTTAAAATCTTCCATTGCAGCTGTAAACAC (−632)

CGATCTGAATTTTAGAAGGTAACGTCGACATTTGTG

The small letters indicate linker nucleotides.

Results and Discussion {#ResultsDiscussion}
======================

To determine whether the CD25 promoter is a target for NF-AT, we cotransfected a CD25 promoter--driven luciferase reporter gene with NF-ATp-- and NF-ATc--specific expression vectors into El4 T and 293 cells. Treatment of 293 cells with TPA plus ionomycin (T+I) led to a \<2-fold, and treatment of El4 cells with T+Con A led to an 8--9-fold, induction of activity of CD25 promoter spanning the nucleotides up to position −2556 ([@B4]), and to a 12-fold induction of a shorter CD25 promoter reaching up to −800. Cotransfection of an NF-ATp expression vector into El4 cells resulted in a strong, 40-fold induction of activity of the longer CD25 promoter and in an up to 60-fold induction of the shorter CD25 promoter fragment after T+Con A treatment of cells (Fig. [1](#F1){ref-type="fig"}). Cotransfection with the NF-ATc vector gave rise to only a slight increase in promoter activity. In 293 cells, the overexpression of both NF-AT factors resulted in a six- to ninefold increase in CD25 promoter activity (Fig. [1](#F1){ref-type="fig"}).

To demonstrate the binding of NF-ATp to the CD25 promoter, GST--NF-ATp encoding its DNA-binding domain was incubated with DNA fragments containing the first 800 bp of the promoter region in DNase I footprint protection assays. Two prominent footprints were detected, spanning the nucleotides from −577 to −587 and −639 to −658, respectively (Fig. [2](#F2){ref-type="fig"} *A*). These comprise the NF-AT "core" binding sequence TGGAA ([@B7]) in opposite orientations (Fig. [2](#F2){ref-type="fig"} *B*). When probes of these oligonucleotides were incubated with GST--NF-ATp in EMSAs, both probes were bound by NF-ATp, whereas a third probe spanning the unprotected nucleotides from −619 to −636 was unable to bind (Fig. [2](#F2){ref-type="fig"} *C*, lanes *13--15*). Using nuclear proteins from murine splenocytes, the generation of typical inducible NF-AT complexes was detected with the −639/−658 probe (Fig. [2](#F2){ref-type="fig"} *C*, lanes *1--6*) and, although far more weakly, with the −577/−587 probe (Fig. [2](#F2){ref-type="fig"} *C*, lanes *7--12*). The generation of these complexes was enhanced after induction of cells with T+I (lanes *1*, *2*, *7*, and *8*) and efficiently competed with a 100-fold molar excess of the distal IL-2 NF-AT site (Fig. [2](#F2){ref-type="fig"} *C*, lanes *6* and *12*). Moreover, the complexes were supershifted in EMSAs using NF-ATp-- and NF-ATc--specific Abs (lanes *3*, *4*, *9*, and *10*).

The −639/−658 site corresponds to a high-affinity NF-AT binding site. This could be seen best in EMSA competition assays comparing the binding of NF-AT factors in nuclear protein preparations from T+I--induced Jurkat cells to this site and the distal NF-AT site of the murine IL-2 promoter (Fig. [2](#F2){ref-type="fig"} *D*). Although 5--10 ng of the −639/−658 site was sufficient to suppress almost all NF-AT binding, 10--50 ng of the distal IL-2 NF-AT site was necessary to see the same effect (Fig. [2](#F2){ref-type="fig"} *D*, lanes *6--11*). 50 ng of an AP-1 site was also able to suppress NF-AT complex formation, whereas the same amount of the upstream promoter site, i.e., an efficient octamer but poor AP-1 site from the IL-2 promoter ([@B11]), was without effect on factor binding (Fig. [2](#F2){ref-type="fig"} *D*, lanes *12--15*). In contrast to the −639/−658 site, the −577/−587 NF-ATp binding site is a low-affinity NF-AT site (Fig. [2](#F2){ref-type="fig"} *C*, lanes *7--12*; note that lanes *7--12* were exposed five times longer than lanes *1--6*).

To demonstrate a functional role for the two NF-ATp sites, we introduced mutations into the NF-AT motifs of each site, or into both sites, in the context of the 800-bp wild-type CD25 promoter fragment. These mutations led to a loss of NF-AT binding in EMSAs using nuclear proteins from induced Jurkat cells (see Fig. [2](#F2){ref-type="fig"} *D*, lanes *18--20*) or GST--NF-ATp (data not shown). When the mutated CD25 promoter/luciferase constructs were transfected into El4 T cells alone or with an NF-ATp expression vector their induction was severely impaired compared with the wild-type promoter. The T+Con A--mediated 16-fold induction of the 800-bp CD25 promoter fragment was almost abolished (Fig. [3](#F3){ref-type="fig"} *A*) and its \>25-fold transactivation by NF-ATp was reduced to a 2--3-fold increase for the mutated promoter (Fig. [3](#F3){ref-type="fig"} *B*).

The importance of NF-ATp sites for the CD25 expression is underlined by defects in the CD25 surface expression on LN T cells from NF-ATp^−/−^ mice established in our laboratory ([@B13]). When LN T cells from wild-type mice were stimulated with plate-bound α-CD3 Abs for 2--24 h in vitro, a marked increase of CD25 surface expression was detected after 6--12 h, which became even more pronounced after 24 h. Due to the strong stimulation of the CD25 promoter by secreted IL-2 ([@B2]), \>50% of T cells express large amounts of CD25 48 h after stimulation (Fig. [4](#F4){ref-type="fig"}). On NF-ATp^−/−^ LN T cells, CD25 expression was found to be distinctly delayed, becoming clearly detectable only 24 h after induction in spite of high, unimpaired IL-2 production of NF-ATp^−/−^ T cells ([@B13]). In addition, fewer cells expressed high levels of CD25 after induction for 48 h (Fig. [4](#F4){ref-type="fig"}).

The two NF-ATp binding sites are located near the CD25 promoter and therefore appear to be involved in the rapid induction of the murine CD25 gene in resting T cells. The core sequences of these sites, TGGAA, differ slightly from the AGGAAAA core motifs of the IL-2 and IL-4 promoters and are the strongest NF-ATp binding sites in the human GM-CSF enhancer ([@B14]). As indicated in Fig. [2](#F2){ref-type="fig"} *B*, 7--9 bp 3′ to the NF-AT motifs are situated TPA- responsive element--like sequences that might allow the concerted binding of AP-1 and NF-AT. In EMSAs we detected a specific binding of GST--c-Jun to both sites (data not shown), but it remains to be shown which proteins of the AP-1 family bind and regulate the CD25 promoter in vivo.

Finally, it should be pointed out that several properties of NF-ATp^−/−^ mice, such as the impaired clonal deletion of T cells and expansion of lymphoid organs ([@B13], [@B15], [@B16]), are shared by the mice deficient for IL-2 and IL-2 receptors ([@B17]--[@B19]). We assume that the impaired CD25 expression might contribute to the development of this phenotype in NF-ATp^−/−^ mice, which is reminiscent of other mice with defects in the IL-2 signaling system.
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![NF-ATp transactivates the murine CD25 promoter in T cells. 2.5 μg DNA of luciferase reporter gene constructs controlled by murine CD25 promoters up to position −2556 (wt-2556) and −800 (wt-800) were transfected into murine El4 T thymoma cells or human embryonic 293 kidney cells, along with an empty RSV-based expression vector or vectors expressing NF-ATp ([@B10]) or NF-ATc. The cells were induced as indicated for 18 h. To calculate the extent of induction, the activity of the CD25 wild-type promoter in nonstimulated cells was used as a reference point (onefold).](JEM980127.f1){#F1}

![Binding of NF-AT to the CD25 promoter. (*A*) DNase I footprint protection assay. A CD25 promoter probe spanning the nucleotides from −548 to −804 was incubated with 3 and 5 μg BSA (lanes *3* and *4*) or 1--5 μg GST--NF-ATp protein (lanes *5--9*). The NF-ATp--specific footprints are indicated. *G* and *G*+*A*, chemical sequencing reactions. (*B*) Sequences of footprint regions. The footprints are indicated in brackets. The arrows indicate the direction of TGGAA NF-AT "core" motifs. The TPA responsive element--like sequence motifs 3′ from the NF-AT motifs are boxed. (*C*) EMSAs with the NF-AT sites. In lanes *1--12*, nuclear proteins from murine splenocytes are shown, and in lanes *13--15*, GST--NF-ATp was used with the −639/−658 (lanes *1--6* and *13*) and −577/−587 probes (lanes *7--12* and *15*). In lane *14*, a probe of the −610/−636 site was used as a control. 2 μg of nuclear proteins from uninduced splenocytes (−) or splenocytes induced for 2 h with T+I (+) were incubated in the absence or presence of 0.5 μg NF-ATc-- or NF-ATp--specific Abs, or in the presence of a 200-fold molar excess of homologous unlabeled probes or distal IL-2 NF-AT site as indicated. Note that the autoradiograph of lanes *1--6* was exposed for 16 h, and that of lanes *7--12* for 3 d. *NS*, nonspecific complex. Free probes are cut off. (*D*) EMSAs of the −639/−658 site using nuclear proteins from Jurkat cells. A probe of the −639/−658 site was incubated with 2 μg of nuclear proteins from Jurkat cells treated with T+I in the absence or presence of 100 ng/ml cyclosporin A (*CsA*). For competition the following DNAs were used: 5--50 ng of the cold −639/−658 site and the distal IL-2 NF-AT site, or 10 and 50 ng of the proximal IL-2 octamer site ([@B11]) and a consensus AP-1 site. In lanes *16* and *17*, 0.5 μg of NF-AT--specific Abs were added. In lanes *18--20*, a −632/−667 probe mutated in the NF-AT site (see oligonucleotide *a* in Materials and Methods) was incubated without or with NF-AT--specific Abs.](JEM980127.f2){#F2}

###### 

The NF-ATp sites contribute to the induction of CD25 promoter. (*A*) Mutations within the NF-ATp sites that suppress NF-AT binding interfere with the T+Con A--mediated CD25 promoter induction in El4 cells. 2.5 μg of luciferase constructs containing the wild-type CD25 promoter up to −800 bp or a promoter with mutations in the −658/−639 (*mut. 1*), the −587/−577 site (*mut. 2*), or in both sites (*mut. 1*+*2*) was transfected into El4 cells that were induced for 12 h. (*B*) Mutations of NF-AT sites suppress the NF-ATp--mediated transactivation of the CD25 promoter. 0.5 μg of the CD25 luciferase constructs was cotransfected with an NF-ATp expression vector into El4 cells that were stimulated for 12 h. To calculate the extent of induction, the activity of the CD25 wild-type promoter in nonstimulated cells was used as a reference point (onefold).
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![Impaired CD25 expression on NF-ATp^−/−^ LN T cells. LN T cells from NF-ATp^+/+^ and NF-ATp^−/−^ mice ([@B13]) were treated with plate-bound α-CD3 mAb in vitro. The cells were stained with mAbs directed against murine CD25 (7D4; PharMingen) and α/β-TCR (H57-597; PharMingen). The expression of CD25 on α/β-TCR^+^ LN cells is shown. The lowest panel shows a comparison of CD25 expression on NF-ATp^+/+^ and NF-ATp^−/−^ TCR^+^ LN cells stimulated for 24 h. The dotted line indicates the isotype control staining of LN cells.](JEM980127.f4){#F4}
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